神经内分泌肿瘤的分子放射性诊断与治疗。
Molecular radiotheranostics for neuroendocrine tumours.
机构信息
Royal Free London NHS Foundation Trust, London, UK
Royal Marsden Hospital & Institute of Cancer Research, London, UK.
出版信息
Clin Med (Lond). 2017 Oct;17(5):462-468. doi: 10.7861/clinmedicine.17-5-462.
Abstract
This article discusses the important role of nuclear medicine imaging and therapy in the management of neuroendocrine tumours (NETs). Somatostatin receptor scintigraphy has a high impact on patient management versus conventional imaging. Molecular radiotherapy is an important part of the management of patients with NETs. Selection of patients for molecular radiotherapy in NETs is based on uptake on their radionuclide imaging study. The imaging agent has the same mechanism of uptake as the therapeutic agent. Thus, the imaging study preselects patients that are likely to concentrate radiation within their tumours.
摘要
本文讨论了核医学成像和治疗在神经内分泌肿瘤（NETs）管理中的重要作用。生长抑素受体闪烁显像对患者管理的影响明显高于常规成像。分子放疗是 NETs 患者管理的重要组成部分。NETs 患者进行分子放疗的选择基于其放射性核素成像研究的摄取。成像剂与治疗剂具有相同的摄取机制。因此，成像研究预先选择了那些可能在肿瘤内集中辐射的患者。
相似文献
1
Molecular radiotheranostics for neuroendocrine tumours.神经内分泌肿瘤的分子放射性诊断与治疗。
Clin Med (Lond). 2017 Oct;17(5):462-468. doi: 10.7861/clinmedicine.17-5-462.
2
Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.放射性物质在神经内分泌肿瘤诊断和治疗中的应用。
Scand J Gastroenterol. 2015 Jun;50(6):740-7. doi: 10.3109/00365521.2015.1033454.
3
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.核医学技术在神经内分泌肿瘤的成像和治疗中的应用。
Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S27-51. doi: 10.1530/ERC-10-0282. Print 2011 Oct.
4
Radiopharmaceuticals used for diagnosis and therapy of NETs.用于神经内分泌肿瘤诊断和治疗的放射性药物。
Hell J Nucl Med. 2023 May-Aug;26 Suppl:19-20.
5
The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.放射性标记的间碘苄胍（MIBG）和奥曲肽在神经内分泌肿瘤诊断和管理中的价值。
Ann Oncol. 2001;12 Suppl 2:S47-50. doi: 10.1093/annonc/12.suppl_2.s47.
6
Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.治疗后串联90Y/177Lu-DOTATATE成像的不同技术可能性。
Nucl Med Rev Cent East Eur. 2013;16(2):70-4. doi: 10.5603/NMR.2013.0038.
7
Theranostic in Nuclear Medicine - The paradigm of NET.核医学中的诊疗一体化——神经内分泌肿瘤的范例
Hell J Nucl Med. 2023 May-Aug;26 Suppl:42-43.
8
Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.神经内分泌肿瘤患者的生长抑素受体显像、治疗及新策略
Br J Surg. 2001 Jan;88(1):31-40. doi: 10.1046/j.1365-2168.2001.01644.x.
9
Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.在生长抑素受体阳性肿瘤患者中使用放射性标记的生长抑素类似物进行肽受体放射性核素治疗。
Acta Oncol. 2007;46(6):723-34. doi: 10.1080/02841860701441848.
10
Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?与生长抑素受体闪烁扫描摄取相比，使用生长抑素受体2a亚型免疫组化在预测胃肠胰腺神经内分泌肿瘤反应方面是否具有额外价值？
Neuroendocrinology. 2016;103(5):560-6. doi: 10.1159/000441604. Epub 2015 Nov 5.
引用本文的文献
1
Gene Abnormalities and Modulated Gene Expression Associated with Radionuclide Treatment: Towards Predictive Biomarkers of Response.与放射性核素治疗相关的基因异常和调节基因表达：寻找反应预测性生物标志物。
Genes (Basel). 2024 May 26;15(6):688. doi: 10.3390/genes15060688.
2
Actinium-225 Targeted Agents: Where Are We Now?锕-225 靶向药物：我们现在在哪里？
Brachytherapy. 2023 Nov-Dec;22(6):697-708. doi: 10.1016/j.brachy.2023.06.228. Epub 2023 Sep 9.
3
Combination of [Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model.[镥]镥-多胺基多羧基大环配体-生长抑素类似物靶向放射性核素治疗与光热治疗联合应用作为一种有前景的癌症治疗方法：人源异种移植小鼠模型的体内研究
Pharmaceutics. 2022 Jun 16;14(6):1284. doi: 10.3390/pharmaceutics14061284.
4
Evaluation of Dosimetric Parameters for Tumor Therapy with Lu and Y Radionuclides in Gate Monte Carlo Code.在门控蒙特卡罗代码中对镥和钇放射性核素用于肿瘤治疗的剂量学参数评估
J Biomed Phys Eng. 2021 Jun 1;11(3):263-270. doi: 10.31661/jbpe.v0i0.2101-1256. eCollection 2021 Jun.
5
Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture.利用正电子发射断层显像（PET）成像探索肿瘤异质性：全景概览
Cancers (Basel). 2019 Aug 31;11(9):1282. doi: 10.3390/cancers11091282.
本文引用的文献
1
Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET.镥-177-奥曲肽治疗进展期转移性神经内分泌肿瘤患者的早期疗效及毒性
Nucl Med Commun. 2017 Jul;38(7):593-600. doi: 10.1097/MNM.0000000000000685.
2
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
3
Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.使用¹⁷⁷Lu-DOTATATE的肽受体放射性核素治疗对胰腺神经内分泌肿瘤的剂量反应。
J Nucl Med. 2015 Feb;56(2):177-82. doi: 10.2967/jnumed.114.148437. Epub 2015 Jan 15.
4
Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis.生长抑素受体 PET/CT 在神经内分泌肿瘤中的应用：系统评价和荟萃分析的更新。
Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1770-80. doi: 10.1007/s00259-013-2482-z. Epub 2013 Jul 20.
5
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.18FDG PET/CT 在接受 177Lu-DOTATATE 治疗的晚期分化型神经内分泌肿瘤患者中的作用。
Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):881-8. doi: 10.1007/s00259-013-2369-z. Epub 2013 Feb 27.
6
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.国际原子能机构、欧洲核医学协会和核医学分子影像学会联合发布的神经内分泌肿瘤肽受体放射性核素治疗实践指南。
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16. doi: 10.1007/s00259-012-2330-6.
7
Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.在影像引导治疗中的肽和受体：神经内分泌肿瘤的治疗诊断学。
Semin Nucl Med. 2012 May;42(3):190-207. doi: 10.1053/j.semnuclmed.2012.01.002.
8
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.基于生长抑素的放射性肽治疗 [(90)Y-DOTA]-TOC 与 [(90)Y-DOTA]-TOC 联合 [(177)Lu-DOTA]-TOC 在神经内分泌肿瘤中的队列研究。
J Clin Oncol. 2012 Apr 1;30(10):1100-6. doi: 10.1200/JCO.2011.37.2151. Epub 2012 Mar 5.
9
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).胃肠胰神经内分泌（包括类癌）肿瘤（NETs）管理指南。
Gut. 2012 Jan;61(1):6-32. doi: 10.1136/gutjnl-2011-300831. Epub 2011 Nov 3.
10
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.转移性神经内分泌癌患者接受放射性标记生长抑素类似物[90Y-DOTA]-TOC 治疗后的反应、生存和长期毒性。
J Clin Oncol. 2011 Jun 10;29(17):2416-23. doi: 10.1200/JCO.2010.33.7873. Epub 2011 May 9.
Zotero 插件